BioCryst (BCRX) announced that the Health Services Executive, or HSE, in Ireland has recommended Orladeyo for the routine prevention of recurrent attacks of hereditary angioedema, or HAE, in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. The HSE decision in Ireland follows the European Commission marketing authorization of Orladeyo in April 2021. To date, Orladeyo is licensed in 44 countries.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- Biotech Alert: Searches spiking for these stocks today
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst price target raised to $8 from $7 at Barclays
- BioCryst Pharmaceuticals Reports Strong Q3 2024 Results
- Nvidia to replace Intel on DJIA, Berkshire reports Q3 results: Morning Buzz